RxDoctor Payments Data

Pradeep Arora, MD

Psychiatry · Jacksonville, FLNPI 1366466476

Payments from drug & device makers

$1,118in general payments, 2019–2025

Across 29 payments — averaging $38.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$446
  • Neuronetics, Inc.$223
  • AbbVie$134
  • Acadia Pharmaceuticals Inc$92
  • Johnson & Johnson$75
  • Otsuka America Pharmaceutical, Inc.$45
  • plus $105 from 4 others

What the payments were for

  • Food & beverage$1,118100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,118 in reported general payments places this provider in the 60th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$129,660
Medicare patients
299
Services billed
1,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$91,643
Invega SustennaPaliperidone Palmitate25$57,846
Abilify MaintenaAripiprazole21$50,911
VraylarCariprazine Hcl13$19,067
Lurasidone Hcl27$3,937
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl26$3,769
Ziprasidone Hcl39$2,594
Quetiapine Fumarate65$2,013
Buspirone Hcl73$1,649
Oxcarbazepine16$1,215
Aripiprazole52$1,174
Trazodone Hcl96$1,075
Divalproex Sodium ErDivalproex Sodium32$1,052
Venlafaxine Hcl ErVenlafaxine Hcl26$961
Alprazolam125$952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$75$57,84625 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$45$50,91121 claims
AbbVieVraylar$134$19,06713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →